❌

Normal view

Received — 18 September 2026 ⏭

Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma

✇Nature Medicine
By: Tara Barron · Richard Drexler · Aaron Mochizuki · Evan Cantor · Kiarash Shamardani · Pamelyn J. Woo · Neeraj Soni · Dana Tlais · Andrea Franson · Samantha Lyons · Truman Knowles · Shannon Raber · Vilina Mehta · Michael A. Quezada · Michael B. Keough · Samin Malaki Jahan · Linh Thuy Vo · Enrique Herrera Castañeda · Kathryn R. Taylor · Lijun Ni · Kim Kilian · Samuel H. Wu · Franz L. Ricklefs · Ulrich Schüller · Sabine Mueller · Paul G. Fisher · Cynthia J. Campen · Hannes Vogel · Sonia Partap · Kai Kaila · Carl Koschmann · Michelle Monje
17 September 2026 at 08:00

Nature Medicine, Published online: 17 September 2026; doi:10.1038/s41591-026-04646-6

Results of this study show in experimental models and data from patient cohorts that the antiseizure medication levetiracetam is associated with longer survival and reduced tumor growth in diffuse midline glioma, but not hemispheric high-grade glioma, by selectively dampening GABAergic synaptic signaling, independently of its canonical SV2A-mediated primary antiseizure mechanism.

Type 1 interferon perturbates clonal competition by reshaping human blood development

✇(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Chhiring Lama · Danielle Isakov · Shira Rosenberg · Miguel Quijada-Álamo · Mirca S Saurty-Seerunghen · Sara Moein · Mathis Nozais · Tsega-Ab Abera · Olivia Sakaguchi · Mansi Totwani · Grace Freed · Leila Zaydon · Chi-Lam Poon · Neelang Parghi · Andrea Kubas-Meyer · Amy X Xie · Mohamed Omar · Daniel Choi · Franco Castillo-Tokumori · Ghaith Abu-Zeinah · Alicia Dillard · Saravanan Ganesan · Nathaniel D Omans · Neville Dusaj · Paulina Chamely · Eleni Mimitou · Peter Smibert · Heidi E Kosiorek · Amylou C Dueck · Rona Weinberg · Ronan Chaligne · Bridget Marcellino · Luigi Marchionni · Sanjay Patel · Paul Simonson · Dan A Landau · Elvin Wagenblast · Ronald Hoffman · Anna S Nam
16 September 2026 at 18:00

Nat Genet. 2026 Sep 15. doi: 10.1038/s41588-026-02751-3. Online ahead of print.

ABSTRACT

Inflammation accelerates evolutionary dynamics of hematopoietic stem cells (HSCs) in clonal hematopoiesis and myeloid neoplasms. We studied HSCs, progenitors and immune cells from patients with myeloproliferative neoplasms at baseline and following interferon-α (IFNα) treatment, the only therapy to deplete mutated stem cells. We deployed single-cell multiomics methods that distinguish the IFNα effects on mutated stem cells from the admixed wild-type HSCs, with respect to their differentiation, transcriptomes, immunophenotypes and chromatin accessibility. IFNα simultaneously activated HSCs into two polarized states: a lymphoid progenitor expansion associated with an anti-inflammatory state and an inflammatory myeloid progenitor state derived from HSCs. The augmented lymphoid differentiation balanced the typical myeloproliferative-neoplasm-induced myeloid bias, associated with normalized blood counts. Somatic mutations modified the effects of IFNα on HSC differentiation and cell cycle entry rates. Clonal fitness upon IFNα exposure was due to resistance of CALR- or JAK2-mutated stem cells to differentiate into inflammatory myeloid progenitors.

PMID:42745000 | DOI:10.1038/s41588-026-02751-3

rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model

✇Cell Death Discovery nature.com science feeds
By: Davide Vecchiotti · Mauro Di Vito Nolfi · Chiara Compagnoni · Martina Sara Miscione · Daniela Verzella · Daniel D’Andrea · Irene Flati · Francesca Galli · Michele d’Angelo · Adriano Angelucci · Franca Cattani · Annamaria Cimini · Alessandra Tessitore · Daria Capece · Edoardo Alesse · Marcello Allegretti · Francesca Zazzeroni
16 September 2026 at 08:00

Cell Death Discovery, Published online: 16 September 2026; doi:10.1038/s41420-026-03345-y

rhNGF shows neuroprotective efficacy by counteracting oxidative stress and neuroinflammation in a glaucoma mouse model

Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial

✇Nature Medicine
By: Marcilio J. Fumagalli · Anna Kaczynska · Marius Allombert · Ágata Lopes-Ribeiro · Mariângela de Oliveira Silva · Brianna J. Hernandez · Christy Lavine · Sebastian M. Espinosa · Helen Brown · Hanna Box · Emanuela Falaschetti · Louise-Rae Cherrill · Tamara Elliott · Ming Lee · Julie Fox · Sarah Pett · Amanda Clarke · Alison Uriel · Ole Sogaard · Rebecca Sutherland · Marta Boffito · Sabine Kinloch-Loes · Chloe Orkin · Simon Collins · Panagiota Zacharopoulou · Nicola Robison · Cintia Bittar · Thiago Oliveira · Anna Gazumyan · Mila Jankovic · Michael S. Seaman · John Frater · Marina Caskey · Sarah Fidler · Michel C. Nussenzweig
15 September 2026 at 08:00

Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04644-8

In the phase 2 RIO trial, there was delayed viral rebound and resistance to broadly neutralizing antibodies 3BNC117-LS and 10-1074-LS in adult males living with HIV undergoing analytical treatment interruption, and initial reservoir sensitivity to autologous antibodies was associated with a longer time to rebound.

Predicting cellular responses to perturbation across diverse contexts with State

✇Cell
By: Abhinav K. Adduri · Dhruv Gautam · Beatrice Bevilacqua · Mohsen Naghipourfar · Alishba Imran · Rohan Shah · Noam Teyssier · Rishi Verma · Christopher Carpenter · Basak Eraslan · Francis Chalissery · Rajesh Ilango · Vishvak Subramanyam · Chiara Ricci-Tam · Sanjay Nagaraj · Aidan Winters · Mingze Dong · Stefanie Fellinger · Adam Krejci · Tilmann Burckstummer · Sravya Tirukkovular · Jeremy Sullivan · Brian S. Plosky · Nicholas D. Youngblut · Jure Leskovec · Luke A. Gilbert · Silvana Konermann · Patrick D. Hsu · Alexander Dobin · Dave P. Burke · Hani Goodarzi · Yusuf H. Roohani
31 August 2026 at 08:00
Modeling perturbation effects across large single-cell populations requires flexibility to capture heterogeneity. By training over sets of cells in a shared embedding space, State outperforms baselines at generalizing effects to new contexts. Cell-Eval, the framework used for this comparison, provides a comprehensive benchmark for future models.

The sex and reproductive plasticity of intestinal muscles instruct gut size

✇Cell
By: Alessandro Mineo · Laura Blackie · Alexandra Milona · Emily Strachan · Pedro Gaspar · Nuno Miguel Luis · Alvaro Castano-Medina · Tomotsune Ameku · Bryon Silva · Anadika Prasad · Clara L. Essmann · Jake Jacobson · Todd Fallesen · Vanessa Dao · Sanjay Khadayate · George Young · Filipe Cabreiro · Frank Schnorrer · Irene Miguel-Aliaga
11 August 2026 at 08:00
Adult intestinal size plasticity is driven not only by epithelial stem cells but also by remodeling of the surrounding visceral musculature. Sex- and reproduction-dependent muscle remodeling controls gut size and transit, revealing the intestinal muscle as an active regulator of adult organ adaptation.

Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer

✇Cell
By: Shorook Naara · Veena Kochat · Xiayu Rao · Emre Arslan · Robert Saddawi-Konefka · Suresh Satpati · Jennifer Garbarino · Jennifer L. Anderson · Frederico O. Gleber-Netto · Priyadharsini Nagarajan · Travis D. Kerr · Shamima Akhter · Sophie Li · R’ay Fodor · Shlomo A. Koyfman · Dan Yaniv · Tongxin Xie · Mica Glaun · Michael Bobian · William Israel Padron · Colin Ng · Preethi H. Gunaratne · Shiyanth Thevasagayampillai · Michael R. Migden · Hussein A. Abbas · Patrick K. Reville · Kenneth Y. Tsai · Daniel J. McGrail · Jing Wang · Jeffrey N. Myers · Neil D. Gross · Kunal Rai · Moran Amit
5 August 2026 at 08:00
Spatial multi-omics reveals macrophage states that constrain adaptive immunity in immunosuppressed non-melanoma skin cancer.
There are no more articles
❌